We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AngioGenex Inc (CE) | USOTC:AGGX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0002 | 0.00 | 01:00:00 |
1. Name and Address of Reporting Person * ARONSTEIN MICHAEL | 2. Issuer Name and Ticker or Trading SymbolAngioGenex, Inc. [AGGX] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) __X__ Other (specify below) CHAIRMAN |
3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) | ||
4. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person ___ Form Filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Amount | (A) or (D) | Price | ||||||||
Common Stock | 10/23/2019 | A | 250000 | A | $25000 | 6000000 | D | |||
Common Stock | 12/30/2019 | A | 250000 | A | $25000 | 6000000 | D | |||
Common Stock | 3/3/2020 | A | 25000 | A | $5000 | 6130555 | D | |||
Common Stock | 8/5/2020 | A | 50000 | A | $10000 | 6130555 | D | |||
Common Stock | 10/8/2020 | A | 55555 | A | $10000 | 6130555 | D | |||
Common Stock | 3/2/2021 | A | 400000 | A | $100000 | 7507827 | D | |||
Common Stock | 6/8/2021 | A | 227272 | A | $25000 | 7507827 | D | |||
Common Stock | 8/31/2021 | A | 750000 | A | $100000 | 7507827 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
(A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||||
Stock Option | $0.35 | 1/15/2019 | A | 3000000 | 1/15/2020 | 1/15/2024 | Common Stock | 3000000 | $.035 | 3000000 | D | ||||
Stock Option | $.13 | 9/2/2021 | A | 2000000 | 9/2/2021 | 9/2/2026 | Common Stock | 2000000 | $.13 | 5000000 | D | ||||
Convertible Note | $25 | 11/2/2021 | A | 240000 | 11/2/2021 | 10/31/2023 | Common Stock | 240000 | $.25 | 5240000 | D |
Explanation of Responses: |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
ARONSTEIN MICHAEL 425 MADISON AVE. SUITE 902 NEW YORK, NY 10017 | X | X | CHAIRMAN |
Signatures | ||
/s/ MICHAEL ARONSTEIN | 2/15/2022 | |
**Signature of Reporting Person | Date |
1 Year AngioGenex (CE) Chart |
1 Month AngioGenex (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions